Cleerly Stock
HealthTechLooking to sell Cleerly stock or options?
Cleerly is a developer of a healthcare platform aimed at establishing a new standard of care for coronary artery disease. The company's platform employs a non-invasive method to enhance understanding of plaques, offering detailed quantification and characterization of plaque buildup in the heart's arteries. This enables healthcare providers to significantly enhance the identification of at-risk patients, facilitating early treatment and prevention of heart attacks in a cost-effective manner.
LRVHealth, American College of Cardiology Foundation, Cigna Ventures, Vensana Capital, Battery Ventures, Catalytic Impact Foundation, Highcroft Capital, Piper Sandler, Impact Assets, Sands Capital, DigiTx Partners, Novartis, Pura Vida Investments, Presight Capital, Esplanade Healthtech Ventures, Double Point Ventures, Peter Thiel, Insight Partners, Mirae Asset Capital, Fidelity Management & Research Company, New Leaf Venture, T. Rowe Price Group, Breyer Capital, Gershon Capital, General Catalyst.